Pharma industry 'strategic crisis'


The pharma industry is grappling with a ‘strategic crisis’ according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. The problem is shrinking margins, caused by price and cost pressure, regulatory change and expiring patents.

The top 10 pharma companies increased sales by 13% from 2009 to 2010, but their profits dropped during the same period by 4%. Compounding the problem in the long term, R&D costs have risen 80% over the past 10 years, while the number of new product launches has dropped by 43%.

Emerging markets offer the biggest growth – their market share is set to rise to 40% by 2016. The market for pharmaceutical products will grow on average by 4.5% annually until 2016. But growth in emerging markets will increase by almost 12%. China, Brazil, India and Russia (the so-called BRIC economies) in particular are experiencing high growth.

Half of the companies said they would be willing to move their administration, R&D and sales departments to emerging market regions.


Related Content

Fixing the broken antibiotics business model

13 January 2016 Business

news image

With rising resistance and doomsday warnings, focus is turning to alternative economic models to boost antibiotic R&D

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Most Commented

Countries ink Paris climate change agreement

27 April 2016 News and Analysis

news image

Nearly 200 countries signed the global climate treaty that aims to limit temperature rises to ‘well below’ 2°C

Shadow of Chernobyl

26 April 2016 Critical Point

news image

Mark Peplow takes the long view on the cost of nuclear power